Log in

Relevant bibliographies by topics / Azole

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Azole'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Azole.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Azole"

1

Laing, R. B. S., R. P. Brettle, and C. L. S. Leen. "Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients." International Journal of STD & AIDS 9, no. 1 (January 1, 1998): 16–20. http://dx.doi.org/10.1258/0956462981920973.

Full text

Abstract:

Summary: A retrospective review of AIDS-related oesophageal candidiasis was undertaken to identify clinical features helpful in predicting response to azole therapy and patient survival. Patients who had received daily azole prophylaxis against candidiasis were significantly less likely to respond to azole therapy than < those who had not ( P 0.001). Patients who had lost the 2 months before oesophageal candidiasis were less likely to respond to azoles < than the others ( P 0.001). Amongst those who had not received daily azoles, < + patients with a CD4 cell count 25/mm were less likely to respond to azole treatment ( P = 0.05). The median survival beyond oesophageal candidiasis was 18 months. Survival from oesophageal candidiasis was significantly poorer for patients who did not respond to azole therapy but AIDS survival did not differ between azole responders and non-responders. Non-responders who had been taking daily azole prophylaxis had the poorest survival (median = 4 months). > 5% of their body weight in 3

APA, Harvard, Vancouver, ISO, and other styles

2

Serfling, Albrecht, Johannes Wohlrab, and Holger B. Deising. "Treatment of a Clinically Relevant Plant-Pathogenic Fungus with an Agricultural Azole Causes Cross-Resistance to Medical Azoles and Potentiates Caspofungin Efficacy." Antimicrobial Agents and Chemotherapy 51, no. 10 (July 9, 2007): 3672–76. http://dx.doi.org/10.1128/aac.00654-07.

Full text

Abstract:

ABSTRACT Azoles are extensively applied in agriculture and medicine, and a relationship between the development of azole resistance in agriculture and the development of azole resistance in clinical practice may exist. The maize pathogen Colletotrichum graminicola, causing cutaneous mycosis and keratitis, has been used to investigate the acquisition of resistance to an agricultural azole and the resulting cross-resistance to various medical antifungal agents. Azole-adapted strains were less sensitive to all azoles tested but showed increased sensitivity to caspofungin, amphotericin B, and nystatin. Viability staining and infection assays with excised human skin confirmed these data.

APA, Harvard, Vancouver, ISO, and other styles

3

van Ingen, Jakko, Henrich A. L. van der Lee, Antonius J. M. M. Rijs, Eveline Snelders, Willem J. G. Melchers, and Paul E. Verweij. "High-Level Pan-Azole-Resistant Aspergillosis: TABLE 1." Journal of Clinical Microbiology 53, no. 7 (April 22, 2015): 2343–45. http://dx.doi.org/10.1128/jcm.00502-15.

Full text

Abstract:

High-level pan-azole-resistantAspergillus fumigatuswas recovered from four patients with chronic lung disease. In one patient, the development of progressive resistance followed long-term azole therapy and switching between antifungal azoles. The high-level pan-azole-resistant phenotypes were not associated with a specificcyp51Agene mutation. New strategies that avoid the development of progressive azole resistance are needed.

APA, Harvard, Vancouver, ISO, and other styles

4

Gonzalez-Jimenez, Irene, Jose Lucio, Alejandra Roldan, Laura Alcazar-Fuoli, and Emilia Mellado. "Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in Aspergillus fumigatus?" Molecules 26, no. 19 (October 1, 2021): 5975. http://dx.doi.org/10.3390/molecules26195975.

Full text

Abstract:

Invasive aspergillosis, mainly caused by Aspergillus fumigatus, can lead to severe clinical outcomes in immunocompromised individuals. Antifungal treatment, based on the use of azoles, is crucial to increase survival rates. However, the recent emergence of azole-resistant A. fumigatus isolates is affecting the efficacy of the clinical therapy and lowering the success rate of azole strategies against aspergillosis. Azole resistance mechanisms described to date are mainly associated with mutations in the azole target gene cyp51A that entail structural changes in Cyp51A or overexpression of the gene. However, strains lacking cyp51A modifications but resistant to clinical azoles have recently been detected. Some genes have been proposed as new players in azole resistance. In this study, the gene hmg1, recently related to azole resistance, and its paralogue hmg2 were studied in a collection of fifteen azole-resistant strains without cyp51A modifications. Both genes encode HMG-CoA reductases and are involved in the ergosterol biosynthesis. Several mutations located in the sterol sensing domain (SSD) of Hmg1 (D242Y, G307D/S, P309L, K319Q, Y368H, F390L and I412T) and Hmg2 (I235S, V303A, I312S, I360F and V397C) were detected. The role of these mutations in conferring azole resistance is discussed in this work.

APA, Harvard, Vancouver, ISO, and other styles

5

Sanglard, Dominique, and Alix T. Coste. "Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms." Antimicrobial Agents and Chemotherapy 60, no. 1 (October 19, 2015): 229–38. http://dx.doi.org/10.1128/aac.02157-15.

Full text

Abstract:

ABSTRACTIsavuconazole is a novel, broad-spectrum, antifungal azole. In order to evaluate its interactions with known azole resistance mechanisms, isavuconazole susceptibility among different yeast models and clinical isolates expressing characterized azole resistance mechanisms was tested and compared to those of fluconazole, itraconazole, posaconazole, and voriconazole.Saccharomyces cerevisiaeexpressing theCandida albicansandC. glabrataATP binding cassette (ABC) transporters (CDR1,CDR2, andCgCDR1), major facilitator (MDR1), and lanosterol 14-α-sterol-demethylase (ERG11) alleles with mutations were used. In addition, pairs ofC. albicansandC. glabratastrains from matched clinical isolates with known azole resistance mechanisms were investigated. The expression of ABC transporters increased all azole MICs, suggesting that all azoles tested were substrates of ABC transporters. The expression ofMDR1did not increase posaconazole, itraconazole, and isavuconazole MICs. Relative increases of azole MICs (from 4- to 32-fold) were observed for fluconazole, voriconazole, and isavuconazole when at least two mutations were present in the sameERG11allele. Upon MIC testing of azoles with clinicalC. albicansandC. glabrataisolates with known resistance mechanisms, the MIC90s ofC. albicansfor fluconazole, voriconazole, itraconazole, posaconazole, and isavuconazole were 128, 2, 1, 0.5, and 2 μg/ml, respectively, while inC. glabratathey were 128, 2, 4, 4, and 16 μg/ml, respectively. In conclusion, the effects of azole resistance mechanisms on isavuconazole did not differ significantly from those of other azoles. Resistance mechanisms in yeasts involving ABC transporters andERG11decreased the activity of isavuconazole, whileMDR1had limited effect.

APA, Harvard, Vancouver, ISO, and other styles

6

Liepa, AJ, AJ Liepa, TC Morton, and TC Morton. "Synthesis of 1-(α-Acyloxy-2-hydroxybenzyl)Azoles and Related Compounds by an Acyl Transfer Reaction." Australian Journal of Chemistry 42, no. 11 (1989): 1961. http://dx.doi.org/10.1071/ch9891961.

Full text

Abstract:

Novel azole adducts were produced by reaction of azoles and 2-acyloxyaryl aldehydes. The mechanism of the reaction involves attack by the azole at the carbonyl group and transfer of the acyl group to form an azole-substituted benzylic ester. 2-Acyloxyaryl ketones did not undergo an analogous reaction. An aminal was formed rather than an azole-substituted benzylic carbonate when a 2-aryl aldehyde carbonate was used as substrate.

APA, Harvard, Vancouver, ISO, and other styles

7

Gonzalez-Jimenez, Irene, Jose Lucio, Jorge Amich, Isabel Cuesta, Rafael Sanchez Arroyo, Laura Alcazar-Fuoli, and Emilia Mellado. "A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus." Journal of Fungi 6, no. 4 (November 26, 2020): 315. http://dx.doi.org/10.3390/jof6040315.

Full text

Abstract:

The emergence and spread of Aspergillus fumigatus azole resistance has been acknowledged worldwide. The main problem of azole resistance is the limited therapeutic options for patients suffering aspergillosis. Azole resistance mechanisms have been mostly linked to the enzyme Cyp51A, a target of azole drugs, with a wide variety of modifications responsible for the different resistance mechanisms described to date. However, there are increasing reports of A. fumigatus strains showing azole resistance without Cyp51A modifications, and thus, novel resistance mechanisms are being explored. Here, we characterized two isogenic A. fumigatus clinical strains isolated two years apart from the same patient. Both strains were resistant to clinical azoles but showed different azole resistance mechanisms. One strain (CM8940) harbored a previously described G54A mutation in Cyp51A while the other strain (CM9640) had a novel G457S mutation in Cyp51B, the other target of azoles. In addition, this second strain had a F390L mutation in Hmg1. CM9640 showed higher levels of gene expression of cyp51A, cyp51B and hmg1 than the CM8940 strain. The role of the novel mutation found in Cyp51B together with the contribution of a mutation in Hmg1 in azole resistance is discussed.

APA, Harvard, Vancouver, ISO, and other styles

8

Ghannoum, Mahmoud. "Azole Resistance in Dermatophytes." Journal of the American Podiatric Medical Association 106, no. 1 (January 1, 2016): 79–86. http://dx.doi.org/10.7547/14-109.

Full text

Abstract:

Azole antifungal agents (eg, fluconazole and itraconazole) have been widely used to treat superficial fungal infections caused by dermatophytes and, unlike the allylamines (such as terbinafine and naftifine), have been associated with resistance development. Although many published manuscripts describe resistance to azoles among yeast and molds, reports describing resistance of dermatophytes are starting to appear. In this review, I discuss the mode of action of azole antifungals and mechanisms underlying their resistance compared with the allylamine class of compounds. Data from published and original studies were compared and summarized, and their clinical implications are discussed. In contrast to the cidal allylamines, static drugs such as azoles permit the occurrence of mutations in enzymes involved in ergosterol biosynthesis, and the ergosterol precursors accumulating as a consequence of azole action are not toxic. Azole antifungals, unlike allylamines, potentiate resistance development in dermatophytes.

APA, Harvard, Vancouver, ISO, and other styles

9

Mortensen, Klaus Leth, Emilia Mellado, Cornelia Lass-Flörl, Juan Luis Rodriguez-Tudela, Helle Krogh Johansen, and Maiken Cavling Arendrup. "Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain." Antimicrobial Agents and Chemotherapy 54, no. 11 (August 30, 2010): 4545–49. http://dx.doi.org/10.1128/aac.00692-10.

Full text

Abstract:

ABSTRACT A single mechanism of azole resistance was shown to predominate in clinical and environmental Aspergillus fumigatus isolates from the Netherlands, and a link to the use of azoles in the environment was suggested. To explore the prevalence of azole-resistant A. fumigatus and other aspergilli in the environment in other European countries, we collected samples from the surroundings of hospitals in Copenhagen, Innsbruck, and Madrid, flowerbeds in an amusement park in Copenhagen, and compost bags purchased in Austria, Denmark, and Spain and screened for azole resistance using multidish agars with itraconazole, voriconazole, and posaconazole. EUCAST method E.DEF 9.1 was used to confirm azole resistance. The promoter and entire coding sequence of the cyp51A gene were sequenced to identify azole-resistant A. fumigatus isolates. A. fumigatus was recovered in 144 out of 185 samples (77.8%). Four A. fumigatus isolates from four Danish soil samples displayed elevated azole MICs (8%), and all harbored the same TR/L98H mutation of cyp51A. One A. lentulus isolate with voriconazole MIC of 4 mg/liter was detected in Spain. No azole-resistant aspergilli were detected in compost. Finally, A. terreus was present in seven samples from Austria. Multi-azole-resistant A. fumigatus is present in the environment in Denmark. The resistance mechanism is identical to that of environmental isolates in the Netherlands. No link to commercial compost could be detected. In Spain and Austria, only Aspergillus species with intrinsic resistance to either azoles or amphotericin B were found.

APA, Harvard, Vancouver, ISO, and other styles

10

Das, Rina, Gyati S. Asthana, Krishan A. Suri, Dinesh Mehta, and Abhay Asthana. "Recent Developments in Azole Compounds as Antitubercular Agent." Mini-Reviews in Organic Chemistry 16, no. 3 (January 25, 2019): 290–306. http://dx.doi.org/10.2174/1570193x15666180622144414.

Full text

Abstract:

Tuberculosis (TB) is a global health disaster and is a wide-reaching hitch. The improper use of antibiotics in chemotherapy of TB patients led to the current problem of tuberculosis therapy which gives rise to Multi-Drug Resistant (MDR) strains. Nitrogen heterocycles including azole compounds are an important class of therapeutic agent with electron-rich property. Azole-based derivatives easily bind with the enzymes and receptors in organisms through noncovalent interactions, thereby possessing various applications in medicinal chemistry. Research on azoles derivatives have been expansively carried out and have become one of the extremely active area in recent years and the progress is quite rapid. A genuine attempt to review chemistry of azoles and to describe various azole-based compounds synthesized in the last two decades having promising antitubercular potential is described in the present article. It is hopeful that azole compounds may continue to serve as an important direction for the exploitation of azole-based antitubercular drugs with better curative effect, lower toxicity, less side effects, especially fewer resistances and so on.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Azole"

1

Miró, Sabaté Carlos Hector. "Azole-based energetic materials." Diss., lmu, 2008. http://nbn-resolving.de/urn:nbn:de:bvb:19-99477.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Howard, Susan J. "Azole Resistance in Aspergillus." Thesis, University of Manchester, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.503743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sabzevari, Omid. "Azole antifungal drugs and cytochrome P450 induction." Thesis, University of Surrey, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359878.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Albarrag, Ahmed. "Azole resistance in clinical isolates of Aspergillus fumigatus." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.487927.

Full text

Abstract:

Aspergillus fil1nigatus is the most common aetiological agent of aspergillosis. Invasive aspergillosis is a major cause of death in leukaemic and organ transplant patients. The azoles are the largest and the most widely used class of antifungals. Antifungal drug resistance has been observed in many fungi. In many organisms, acquiring resistance to a drug can confer a biological fitness cost that is expressed for example as decreased growth rate or virulence. A total number of 21 A. fill11igatus clinical isolates were used in this project. Sixteen of these isolates were recovered serially from four patients at different times during the treatment period with azoles, including three cases of acquired azole resistance. The antifungal susceptibilities of isolates were determined. The genetic relatedness of the isolates was confirmed by microsatellite length polymorphism typing. Various measures of fitness were used to determine variation between susceptible and resistant isolates. Growth rate (colony radial growth rate and specific growth rate), germination time and conidial yields were determined on various media. Although some resistant isolates had a reduced growth rate compared to their susceptible match, there was no clear evidence of fitness cost of resistance has been found. The mechanisms of drug resistance in these isolates were investigated. Sequencing of the cyp5JA gene was carried out. Novel and previously described mutations in cyp5JA were identified. Three new mutations were detected in isolates recovered from patient D which were shown to have the same genotype. These mutations were G138C (in six isolates), Y431C (in one isolate) and G434C (in one isolate). These isolates have decreased susceptibility to itraconazole (>8.0 mg/l), voriconazole (4-8.0 mg/l), ravuconazole (4-8.0 mg/l), and posaconazole 0-4.0 mg/l). Azole cross-resistance observed in these isolates was confirmed to be caused by two of these mutations, G138C and Y431C, by expression of the mutated cyp5JA alleles in the yeast S. cerevisiae. The relative levels of expression of cyp5JA, cyp5JB and five efflux transporters, AfuMDRJ, AfilMDR2, AfiIMDR3, AfuMDR4 and atrF, genes were analysed using real-time RT-PCR. Gene expression analysis revealed that isolates from patient D had their cyp5JA gene up-regulated by 7.2- to 13.4-fold. Generally, susceptible and resistant isolates had the same level of expression of all five efflux transporters examined. Interestingly, a type II transposon insertion (1882 bp) in the region upstream of the start codon of cyp5JA, at position -317, was detected in one isolate from patient D, which exhibited the highest level of cyp5JA expression and so transposon insertion was associated with elevation of cyp5JA expression. In conclusion, this thesis describes novel mutations in the cyp5JA gene of clinical isolates that confer and azole cross-resistance. It also identified up-regulation of the cyp5JA gene as an additional azole resistance mechanism in some isolates. An active transposon was identified and found to be associated with resistance by elevating gene expression, an observation not previously made in A. fill11igatus for any phenotype. Up-regulation of 5 transporters and mutations in the cyp5JB gene were not related to resistance.

APA, Harvard, Vancouver, ISO, and other styles

5

Venkateswarlu, Kanamarlapudi. "Azole antifungal drugs mode of action and resistance." Thesis, University of Sheffield, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Marichal, Patrick. "Molecular mechanisms of azole resistance in human pathogenic fungi." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Maastricht University [Host], 1999. http://arno.unimaas.nl/show.cgi?fid=6858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Liu, Teresa T. "Transcriptional regulation of azole antifungal resistance in candida albicans." View the abstract Download the full-text PDF version, 2008. http://etd.utmem.edu/ABSTRACTS/2008-023-Liu-index.html.

Full text

Abstract:

Thesis (M.S.)--University of Tennessee Health Science Center, 2008.
Title from title page screen (viewed on July 31, 2008). Research advisor: P. David Rogers, Pharm.D., Ph.D. Document formatted into pages (xii, 172 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 98-115).

APA, Harvard, Vancouver, ISO, and other styles

8

Lamb, David Christopher. "Cytochrome P450 inhibition and azole antifungal mode of action." Thesis, University of Sheffield, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296853.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Davies, James Robert. "Novel and target specific synthesis of 1,3-azole systems." Thesis, University of Exeter, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.408735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kwok, Iris Man Yan. "The biochemical mode of action of newer azole fungicides." Thesis, University of Bristol, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.336186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Azole"

1

Hargreaves, Judith Ann. Interactions between azole antifungal agents and human microsomal cytochrome P450. Manchester: University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hrnčárová, Nataša. Zákon o azyle: Komentár. Praha: C.H. Beck, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

R, Manson William, and Peale C. George, eds. Atila, azote de Dios. Newark, Del: Juan de la Cuesta, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gesualdo, Alejandro. El azote de Dios. [Buenos Aires]: A. Gesualdo, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

editor, Peale C. George, and Sánchez Jiménez Raquel editor, eds. La Cristianísima Lis y Azote de la Herejía. Newark, Delaware: Juan de la Cuesta, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gribble, Gordon W., ed. Metalation of Azoles and Related Five-Membered Ring Heterocycles. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-31791-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zirngibl, Ludwig. Antifungal azoles: A comprehensive survey of their structures and properties. Weinheim: Wiley-VCH, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sidat, Rehana. The synthesis and analysis of spirobenz-1,3-azoles and related compounds. Leicester: De Montfort University, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Büchel, Karl Heinz. Die Bedeutung der Produktinnovation in der Chemie am Beispiel der Azol-Antimykotika und -Fungizide. Wiesbaden: VS Verlag für Sozialwissenschaften, 1989. http://dx.doi.org/10.1007/978-3-322-88172-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

MacDonald, K. Bruce. Indicator of risk of water contamination: Nitrogen component. Ottawa: Agriculture and Agri-Food Canada, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Azole"

1

Ameen, Mahreen. "Azole Antihelminths." In Handbook of Systemic Drug Treatment in Dermatology, 84–87. 3rd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Holt, Nicolette R., and Karin A. Thursky. "Azole Antifungal Agents." In Drug Dosing in Obesity, 77–96. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-44034-7_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tafi, A., J. Anastassopoulou, M. Botta, F. Corelli, and T. Theophanides. "Azole Fungicides. Comfa Study of Candida Albicans Lanosterol 14α-Demethylase Azole Inhibitors." In Spectroscopy of Biological Molecules, 157–58. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0371-8_72.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Büchel, Karl H. "The History of Azole Chemistry." In ACS Symposium Series, 1–23. Washington, DC: American Chemical Society, 1986. http://dx.doi.org/10.1021/bk-1986-0304.ch001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dodds Ashley, Elizabeth S. "Pharmacology of azole antifungal agents." In Antifungal Therapy, 193–212. Second edition. | New York, NY : CRC Press, [2019]: CRC Press, 2019. http://dx.doi.org/10.1201/9780429402012-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Pintér, Áron, and Gebhard Haberhauer. "Structures of Azole-Containing Macrocyclic Peptides." In Modeling of Molecular Properties, 365–96. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527636402.ch23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cauwenbergh, Geert. "Skin Kinetics of Azole Antifungal Drugs." In Current Topics in Medical Mycology, 88–136. New York, NY: Springer New York, 1992. http://dx.doi.org/10.1007/978-1-4612-2762-5_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Negroni, Ricardo. "Azole Compounds in the Treatment of Paracoccidioidomycosis." In Dimorphic Fungi in Biology and Medicine, 391–96. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2834-0_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Dupont, Bertrand, and Edouard Drouhet. "The Treatment of Aspergillosis with Azole Derivatives." In Aspergillus and Aspergillosis, 243–51. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4899-3505-2_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kelly, S. L., and D. E. Kelly. "Molecular studies on azole sensitivity in fungi." In Molecular Biology and its Application to Medical Mycology, 199–213. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84625-0_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Azole"

1

Gümüş, Selçuk, and Lemi Türker. "Substituent Effect on the Aromaticity of 1,3-Azole Systems." In The 15th International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2011. http://dx.doi.org/10.3390/ecsoc-15-00771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mangalagiu, Ionel, Violeta Mangalagiu, Costel Moldoveanu, Gheorghita Zbancioc, Ramona Danac, and Vasilichia Antoci. "Antimicrobial and anticancer activity of some hybrid azine/azole derivatives." In New frontiers in natural product chemistry, scientific seminar with international participation. Institute of Chemistry, 2021. http://dx.doi.org/10.19261/nfnpc.2021.ab07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Canales, D., JM Caro Teller, F. Martínez De La Torre, I. Gonzalez Barrios, JA Hernandez Ramos, MÁ Bruni Montero, and JM Ferrari Piquero. "5PSQ-142 Safety of azole antifungals in transplanted patients receiving tacrolimus." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Todorovic, Smilja, Lígia S. Nobre, Ana Filipa N. Tavares, Peter Hildebrandt, Miguel S. Teixeira, Lígia M. Saraiva, P. M. Champion, and L. D. Ziegler. "Disentangling Interactions of an Azole Antibiotic with a Flavohemoglobin from S. aureus." In XXII INTERNATIONAL CONFERENCE ON RAMAN SPECTROSCOPY. AIP, 2010. http://dx.doi.org/10.1063/1.3482863.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Takeda, Keita, Junko Suzuki, Hideaki Nagai, Masahiro Kawashima, Nobuharu Ohsima, Atsuhisa Tamura, Shinobu Akagawa, et al. "Treatment outcome in patients with chronic pulmonary aspergillosis by azole-resistantaspergillus fumigatus." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Brackin, Amelie P., and Anand Shah. "A longitudinal study investigating patient acquisition of azole resistant Aspergillus fumigatus (ARAf)." In 1st International Conference on Moisture in Buildings 2021. ScienceOpen, 2021. http://dx.doi.org/10.14293/icmb210010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Karanja, Caroline, Weili Hong, Waleed Younis, Ji-Xin Cheng, and Mohamed Seleem. "Aberrant lipogenesis is a metabolic marker for azole-resistant candida albicans (Conference Presentation)." In Multiphoton Microscopy in the Biomedical Sciences XVII, edited by Ammasi Periasamy, Peter T. So, Xiaoliang S. Xie, and Karsten König. SPIE, 2017. http://dx.doi.org/10.1117/12.2255078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zagórska, Agnieszka, Anna Czopek, Magdalena Mielczarek-Puta, Marta Struga, and Marek Bajda. "Synthesis and biological evaluation of mono- and tri-heterocyclic azole derivatives as anticancer agents." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Raposo, M., and Sara Fernandes. "Synthesis and characterization of four novel 1,3-azole based push-pull heterocyclic systems." In The 21st International Electronic Conference on Synthetic Organic Chemistry. Basel, Switzerland: MDPI, 2017. http://dx.doi.org/10.3390/ecsoc-21-04789.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Arvidsson, Lars, and Egil Ravnemyhr. "Laboratory study: Mitigation of sulphidation attacks on copper by use of a Benzo-Tri-Azole derivative." In 2016 IEEE Electrical Insulation Conference (EIC). IEEE, 2016. http://dx.doi.org/10.1109/eic.2016.7548626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!